TrialTargeted oncology2019

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.

Maximilian J Hochmair et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.